Vestronidase alfa

Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Retrieved on: 
Thursday, February 11, 2021

For the fourth quarter of 2020, Ultragenyx reported $91.5 million in total revenue.

Key Points: 
  • For the fourth quarter of 2020, Ultragenyx reported $91.5 million in total revenue.
  • Mepsevii (vestronidase alfa) product sales for the fourth quarter of 2020 were $3.7 million.
  • Total operating expenses for the fourth quarter of 2020 were $187.6 million, including non-cash stock-based compensation of $22.8 million.
  • ET to discuss the fourth quarter and year 2020 financial results and provide a corporate update.

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection

Retrieved on: 
Friday, January 22, 2021

(Clinigen), headquartered in Tokyo, has received on January 22, 2021, Japan manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for mucopolysaccharidosis type II (Hunter syndrome).

Key Points: 
  • (Clinigen), headquartered in Tokyo, has received on January 22, 2021, Japan manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for mucopolysaccharidosis type II (Hunter syndrome).
  • An enzyme-replacement therapy drug for intravenous injection is already in use in Japan and other countries as a treatment for systemic symptoms of mucopolysaccharidosis type II.
  • The approval in Japan is ahead of the world, being the first approval of Hunterase ICV Injection in any country worldwide.
  • Hunterase ICV Injection 15 mg is also the worlds first and only drug for the treatment of central nervous system symptoms of mucopolysaccharidosis type II.